Clinical Trial Update: Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial evaluating SCV-07 for delaying the onset of severe oral mucositis in patients undergoing chemoradiation for head and neck cancer; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• SCV-07 (SCV-07)

Snippet

Sponsor: SciClone Pharmaceuticals | Conditions: Oral Mucositis, Head and Neck Cancer | Phase 2 | Status: COMPLETED